JDQ443 for Cancer
(KontRASt-01 Trial)
Recruiting at51 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Novartis Pharmaceuticals
No Placebo Group
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug, JDQ443, alone and with two other drugs, in patients with advanced solid tumors. It aims to find the safest dose and see if the combination can effectively reduce tumors.
Research Team
Eligibility Criteria
This trial is for adults with advanced solid tumors that have a specific mutation called KRAS G12C. They should have tried standard treatments or be unable to take them, and may have had previous KRAS G12C inhibitor treatment. Participants need at least one tumor that can be measured and must be fairly active and able to care for themselves.Inclusion Criteria
You have at least one specific type of visible abnormality that can be measured according to a specific set of guidelines.
I may have been treated with a KRAS G12C inhibitor before.
I have advanced cancer with a KRAS G12C mutation and can't take standard treatments.
See 1 more
Exclusion Criteria
My tumor has a specific mutation, but not the KRAS G12C mutation.
Other protocol-defined inclusion/exclusion criteria may apply.
I have brain metastases but do not have symptoms, or they are treated.
See 2 more
Treatment Details
Interventions
- JDQ443 (Other)
Trial OverviewThe study is testing the safety and effectiveness of JDQ443 alone, and in combination with TNO155 or tislelizumab, in patients with certain advanced cancers. It's an early-phase trial where doses are increased until they find the highest dose people can tolerate without severe side effects.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Arm DExperimental Treatment3 Interventions
JDQ443 in combination with TNO155 and tislelizumab
Group II: Arm CExperimental Treatment2 Interventions
JDQ443 in combination with tislelizumab
Group III: Arm BExperimental Treatment2 Interventions
JDQ443 in combination with TNO155
Group IV: Arm AExperimental Treatment1 Intervention
JDQ443
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Trials
2,963
Recruited
4,275,000+
Founded
1996
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Gleevec, Cosentyx, Entresto, Kisqali
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD
Related Searches
By Location